Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 15INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Gastric Adenocarcinoma 2Solid Tumor 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1NSCLC 1Mucosal Melanoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Diseases 1Drug-Related Side Effects and Adverse Reactions 1Digestive System Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Tamoxifen 10Docetaxel 8Trastuzumab 7Paclitaxel 6Letrozole 6Gemcitabine 6Exercise 6Control Groups 6exemestane 5Indocyanine Green 5Cyclophosphamide 5Carboplatin 5Anastrozole 5pertuzumab 4dalpiciclib 4Vinorelbine 4Doxorubicin 4Capecitabine 4pyrotinib 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy 3Radiation 3Mammography 3Fulvestrant 3Cisplatin 3ferumoxides 2Zoledronic Acid 2Tablets 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Breast Neoplasms × camrelizumab × Clear all
NCT05475678 2025-01-23

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
369 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡